Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Abionyx Pharma Logo
Abionyx Pharma Growth Score
82
CB Rank
32104
Heat Score
86
ABIONYX Pharma is a biotech company discovering and developing innovative therapies for patients without existing or effective treatment.
Founded
obfuscation
PublicPost-IPO Debt Balma, Midi-Pyrenees, France1-10 www.abionyx.com/en/
Biotechnology
Health Care
Overview

Abionyx Pharma
Total Funding
obfuscation
Growth Score
82
Heat Score
86

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score82
-1 pts
in past quarter
Heat Score 86
13 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Abionyx Pharma

CB Rank
32104
ABIONYX Pharma is a biotech company discovering and developing innovative therapies for patients without existing or effective treatment.
Founded
obfuscation
PublicPost-IPO Debt Balma, Midi-Pyrenees, France1-10 www.abionyx.com/en/
Biotechnology
Health Care

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Grant
OBF
in
obfuscation

Key People

  • Photo of Laurent Guerci
    Laurent Guerci: Chief Digital & Innovation Officer
  • Photo of Rob Scott
    Rob Scott: Chief Medical Officer and Head of Research and Development
    Past Role: AbbVie, Chief Medical Officer, Head of Development

Details

Legal Name ABIONYX Pharma SA
Also Known As Cerenis Therapeutics
Operating Status Active
Stock Symbol  EPA:ABNX
Company Type For Profit
About the Company
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications without effective or existing treatments, even the rarest ones. They provide drugs for the treatment of renal and ophthalmological diseases on a daily basis.
Phone Number +33 5-62-24-97-06
Contact Email infos@abionyx.co
Predictions & Insights

Growth Insight

See this Growth Insight
Abionyx Pharma is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

CER-001
A drug candidate for treating Lecithin-Cholesterol Acyltransferase (LCAT) deficiency and related renal and ophthalmological diseases.
New HDL Vectors for Targeted Drug Delivery
Biotechnological vectors based on HDL particles designed for targeted delivery of drugs to specific tissues.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
1
obfuscation
Fenja CapitalPost-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Fenja Capital Logo
Fenja Capital
Yes
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
—
Fenja Capital Logo
Fenja Capital
Yes
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
—
Fenja Capital Logo
Fenja Capital
Yes
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
—
Fenja Capital Logo
Fenja Capital
Yes
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
—
Fenja Capital Logo
Fenja Capital
Yes
Post-IPO Debt - Abionyx Pharma Logo
Post-IPO Debt - Abionyx Pharma
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 3 Board Members and Advisors 1 Contacts 2

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 17, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

5,351
-61.21%
 in past month

IT Spend

$567.2KThis year, Abionyx Pharma is projected to spend $567.2K on IT, according to Aberdeen.

Actively Used Products

8Abionyx Pharma uses 8 technology products and services including HTML5, Google Analytics, and  Vimeo, according to G2 Stack.

Active Website Tech Count

2Abionyx Pharma is actively using 2 technologies for its website, according to BuiltWith. These include CommonCrawl Top 10m.

Total IP

26The intellectual property of Abionyx Pharma includes 26 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Abionyx Pharma's headquarters? Abionyx Pharma is located in Balma, Midi-Pyrenees, France.Who invested in Abionyx Pharma? Abionyx Pharma has 14 investors including Fenja Capital and  France 2030.When was the last funding round for Abionyx Pharma? Abionyx Pharma closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are Abionyx Pharma's competitors? Alternatives and possible competitors to Abionyx Pharma may include Entrada Therapeutics, Capricor Therapeutics, and  Pepgen.How much funding has Abionyx Pharma raised to date? Abionyx Pharma has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ab5958e 1)
|